APP and Alzheimer disease: In terms of the ACH2.0, it can be safely assumed that any drug lowering the extracellular Aβ levels (and, consequently, reducing its cellular uptake), including multiple Aβ-sequestering monoclonal antibodies, or inhibiting AβPP proteolysis, such as verubecestat, would have a similar effect if administered at the same early symptomatic AD stage, provided that their potential cellular toxicity would not obscure their therapeutic impact.